Mycophenolate mofetil in treatment of steroid-resistant nephrotic syndrome in children

L.S. Prikhodina, O.Yu. Turpitko, V.V. Dlin, M.S. Ignatova

Aim. Assessment of efficacy and safety of micofenolat mofetil in treatment of primary steroid-resistant nephrotic syndrome in children.
Methods. 18 children with primary non-familial steroid-resistant nephrotic syndrome (7 patients with focal-segmental glomerulosclerosis, 7 – with mesangioproliferative glomerulonephritis, (GN), 3 - with minimal change nephrotic syndrome, 1 – with membranoproliferative GN) were included into the study. Mycophenolate mofetil was 31,8 mg/kg/24h was dispensed with methylprednisolone (0,5-1,0 mg/kg/48h).
Results. Complete clinical and laboratory remission was achieved in 22% of patients, partial – in 28%, 50% demonstrated no effect. Efficacy of micofenolat mofetil did not depend of morphological type of nephrotic syndrome. Adverse events were registered in 28% patients: immunodepression in 17%, anemia - in 11%.
Conclusion. Micofenolat mofetil сan induce complete or partial remission in 50% of children with steroid-resistant nephrotic syndrome.

Similar Articles

Бионика Медиа